Data from: Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke

Luke Lemmerman, Maria Balch, Jordan Moore, Diego Alzate-Correa, Maria Rincon-Benavides, Ana Salazar-Puerta, Surya Gnyawali, Hallie Harris, William Lawrence, Lilibeth Ortega-Pineda, Lauren Wilch, Ian Risser, Aidan Maxwell, Silvia Duarte-Sanmiguel, Daniel Dodd, Gina Guio-Vega, Dana McTigue, William Arnold, Shahid Nimjee, Chandan Sen, Savita Khanna, Cameron Rink, Natalia Higuita-Castro & Daniel Gallego-Perez
Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to significant functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here we used fibroblasts nanotransfected with Etv2, Foxc2, and Fli1 (EFF), to drive reprogramming-based vasculogenesis, intracranially, as a potential therapy for ischemic stroke. Perfusion analyses suggest that intracranial delivery of EFF-nanotransfected fibroblasts led to a dose-dependent increase...
45 views reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
1 download reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?